Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

(2019) Scott T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

(2018) Amanda N. Fader et al.   JOURNAL OF CLINICAL ONCOLOGY

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

(2018) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

(2017) Aiko Nagayama et al.   Targeted Oncology

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

(2013) Natalia Buza et al.   MODERN PATHOLOGY

Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway

(2013) Ting Liu et al.   PLoS One

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

(2013) S. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody

(2011) Joyce Varughese et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

(2009) K El-Sahwi et al.   BRITISH JOURNAL OF CANCER

Follow-up for women after treatment for cervical cancer: A systematic review

(2009) Laurie Elit et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY